Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 8/20 | 0.78 |
| ▸ | ALDH1A3 | P47895 | 6/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | ALDH1A2 | O94788 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1474451 | 0.99 | NR4A2 (0.77) | NR4A2ALDH1A3ALDH1A1KCNH2CYP2C9 | |
| SCHEMBL1474903 | 0.91 | NR4A2 (0.70) | NR4A2ALDH1A3ALDH1A1KCNH2CYP2C9 | |
| SCHEMBL2064292 | 0.88 | NR4A2 (1.00) | NR4A2ALDH1A3ALDH1A1KCNH2CYP2C9 | |
| SCHEMBL2063933 | 0.88 | NR4A2 (0.76) | NR4A2ALDH1A3ALDH1A1KCNH2CYP2C9 | |
| SCHEMBL1472557 | 0.84 | NR4A2 (0.60) | NR4A2ALDH1A3ALDH1A1KCNH2CYP2C9 | |
| Hydrochloric Acid SCHEMBL1472509 | 0.83 | NR4A2 (0.59) | NR4A2ALDH1A3ALDH1A1KCNH2CYP2C9 | |
| SCHEMBL13269546 | 0.83 | NR4A2 (0.69) | NR4A2ALDH1A3ALDH1A1KCNH2CYP2C9 | |
| SCHEMBL3427625 | 0.81 | NR4A2 (0.55) | NR4A2ALDH1A3ALDH1A1KCNH2CYP2C9 | |
| SCHEMBL2063551 | 0.81 | NR4A2 (0.77) | NR4A2ALDH1A3ALDH1A1KCNH2CYP2C9 | |
| Hydrochloric Acid SCHEMBL6518944 | 0.81 | NR4A2 (0.54) | NR4A2ALDH1A3ALDH1A1KCNH2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915284-B2 | 2-aryl-6-phenylimidazo[1,2-a]pyridine derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2011-03-29 | — | — | US | claimed |
| EP-2069342-B1 | 2-ARYL-6-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2010-05-12 | — | — | EP | claimed |
| US-20090253735-A1 | 2-ARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-10-08 | — | — | US | claimed |
| US-7915284-B2 | 2-aryl-6-phenylimidazo[1,2-a]pyridine derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2011-03-29 | — | — | US | disclosed |
| EP-2069342-B1 | 2-ARYL-6-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2010-05-12 | — | — | EP | disclosed |
| US-20090253735-A1 | 2-ARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253735-A1 | 2-ARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | NCOR1, NR4A2, NR4A3 | NR4A2 2/4885ALDH1A3 1043/4885ALDH1A1 1788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.